← Leaderboards
Lauren Averett Byers
University Of Tx Md Anderson Can Ctr
$9,117,683
Attributed
$17,657,267
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2016–25$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,657,267 · 6
By mechanism
U24$6,056,429 · 1
U01$5,995,893 · 2
R01$3,340,910 · 1
P50$2,264,035 · 2
Top collaborators
- John V. Heymach10 shared
- Julien Sage5 shared
- Jianjun Zhang5 shared
- John D Minna4 shared
- Trudy Gale Oliver4 shared
- Charles M Rudin4 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- John V. Heymach$11,138,593
- Jianjun Zhang$2,808,388
- Jae-Il Park$5,811,462
- Ann Klopp$166,188
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant NeoplasmsClinical TrialsIn VivoDna DamageResponseCancer PatientBioinformaticsResistancePre-ClinicalImmunotherapyResearch PersonnelPredictive MarkerIn VitroImmunePre-Clinical ModelMediatingMouse ModelLaboratoriesPharmaceutical PreparationsChemotherapyPathway InteractionsPatient Derived Xenograft ModelVirtual
Grant awards (28)
Coordinating center for the NCI small cell lung cancer research consortium$1,379,839
U24 · FY2025 · CA
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response$605,520
U01 · FY2025 · CA · contact PI
DNA damaging therapy and immune response in small cell lung cancer subtypes$387,250
R01 · FY2025 · CA · contact PI
Coordinating center for the NCI small cell lung cancer research consortium$1,456,493
U24 · FY2024 · CA
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response$575,245
U01 · FY2024 · CA · contact PI
Project 4: Therapeutic Targeting of Replication Stress Vulnerabilities in Small Cell Lung Cancer$478,337
P50 · FY2024 · CA · contact PI
DNA damaging therapy and immune response in small cell lung cancer subtypes$367,887
R01 · FY2024 · CA · contact PI
Coordinating center for the NCI small cell lung cancer research consortium$1,565,497
U24 · FY2023 · CA
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response$561,956
U01 · FY2023 · CA · contact PI
Project 4: Therapeutic Targeting of Replication Stress Vulnerabilities in Small Cell Lung Cancer$424,710
P50 · FY2023 · CA · contact PI
DNA damaging therapy and immune response in small cell lung cancer subtypes$379,504
R01 · FY2023 · CA · contact PI
Coordinating center for the NCI small cell lung cancer research consortium$1,654,600
U24 · FY2022 · CA
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response$593,411
U01 · FY2022 · CA · contact PI
Project 4: Therapeutic Targeting of Replication Stress Vulnerabilities in Small Cell Lung Cancer$424,709
P50 · FY2022 · CA · contact PI
DNA damaging therapy and immune response in small cell lung cancer subtypes$387,250
R01 · FY2022 · CA · contact PI
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response$620,991
U01 · FY2021 · CA · contact PI
Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC$551,067
U01 · FY2021 · CA
Project 4: Therapeutic Targeting of Replication Stress Vulnerabilities in Small Cell Lung Cancer$463,389
P50 · FY2021 · CA · contact PI
Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC$702,580
U01 · FY2020 · CA
Project 4: Therapeutic Targeting of Replication Stress Vulnerabilities in Small Cell Lung Cancer$472,890
P50 · FY2020 · CA · contact PI
Therapeutic strategies for targeting PARP1 in small cell lung cancer$366,000
R01 · FY2020 · CA · contact PI
Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC$573,659
U01 · FY2019 · CA
Therapeutic strategies for targeting PARP1 in small cell lung cancer$355,019
R01 · FY2019 · CA · contact PI
Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC$596,039
U01 · FY2018 · CA
Therapeutic strategies for targeting PARP1 in small cell lung cancer$366,000
R01 · FY2018 · CA · contact PI
Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC$615,425
U01 · FY2017 · CA
Therapeutic strategies for targeting PARP1 in small cell lung cancer$366,000
R01 · FY2017 · CA · contact PI
Therapeutic strategies for targeting PARP1 in small cell lung cancer$366,000
R01 · FY2016 · CA · contact PI